The Technical University of Munich (TUM), Ludwig Maximilian University (LMU) and the University of Würzburg have joined forces to launch the new NUCLEATE Cluster of Excellence. This cluster is focused on uncovering the function and regulation of nucleic acids. Alongside its emphasis on fundamental RNA and DNA research, the cluster promotes the development of novel nucleic acid-based therapies – a goal that closely aligns with RNATICS’ mission.
Prof. Dr. Dr. Stefan Engelhardt, founder and CSO of RNATICS and one of the cluster’s three spokespeople commented, “We are witnessing a revolution in nucleic acid research.”
We are witnessing a revolution in nucleic acid research.
Prof. Dr. Dr. Stefan Engelhardt, founder and CSO of RNATICS
Leading the way in nucleic acid therapy, we at RNATICS use cutting-edge carbohydrate coupling technology to deliver RNA therapeutics directly to lung macrophages. Our lead candidate, RCS-21, utilizes this innovative delivery system to selectively inhibit miR-21 in macrophages, a key microRNA driving inflammation and fibrosis (Beck et al., Nat Commun). RCS-21 represents a breakthrough in targeted RNA therapy, offering new hope for patients suffering from acute and chronic inflammatory lung diseases.
There’s a lot happening in this field right now, and we’re a major part of it.
Dr. Christina Beck, RNATICS
Through a strong collaboration between academic research and industry, we are pioneering the future of nucleic acid therapies and advancing patient care worldwide.